Activity of the HMGB1-derived immunostimulatory peptide Hp91 resides in the helical C-terminal portion and is enhanced by dimerization

R. Saenz, B. Messmer, D. Futalan, Y. Tor, M. Larsson, G. Daniels, Sadik Esener, D. Messmer

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We have previously shown that an 18 amino acid long peptide, named Hp91, whose sequence corresponds to a region within the endogenous protein HMGB1, activates dendritic cells (DCs) and acts as adjuvant in vivo by potentiating Th1-type antigen-specific immune responses. We analyzed the structure-function relationship of the Hp91 peptide to investigate the amino acids and structure responsible for immune responses. We found that the cysteine at position 16 of Hp91 enabled formation of reversible peptide dimmers, monomer and dimmer were compared for DC binding and activation. Stable monomers and dimers were generated using a maleimide conjugation reaction. The dimer showed enhanced ability to bind to and activate DCs. Furthermore, the C-terminal 9 amino acids of Hp91, named UC1018 were sufficient for DC binding and Circular dichroism showed that UC1018 assumes an alpha-helical structure. The ninemer peptide UC1018 induced more potent antigen-specific CTL responses in vivo as compared to Hp91 and it protected mice from tumor development when used in a prophylactic vaccine setting. We have identified a short alpha helical peptide that acts as potent adjuvant inducing protective immune responses in vivo.

Original languageEnglish (US)
Pages (from-to)191-199
Number of pages9
JournalMolecular Immunology
Volume57
Issue number2
DOIs
StatePublished - Feb 2014
Externally publishedYes

Fingerprint

HMGB1 Protein
Dimerization
Dendritic Cells
Peptides
Amino Acids
Histocompatibility Antigens Class II
Circular Dichroism
Cysteine
Vaccines
Antigens
Neoplasms

Keywords

  • Adjuvant
  • Dendritic cells
  • Immune response
  • Peptide

ASJC Scopus subject areas

  • Molecular Biology
  • Immunology

Cite this

Activity of the HMGB1-derived immunostimulatory peptide Hp91 resides in the helical C-terminal portion and is enhanced by dimerization. / Saenz, R.; Messmer, B.; Futalan, D.; Tor, Y.; Larsson, M.; Daniels, G.; Esener, Sadik; Messmer, D.

In: Molecular Immunology, Vol. 57, No. 2, 02.2014, p. 191-199.

Research output: Contribution to journalArticle

Saenz, R. ; Messmer, B. ; Futalan, D. ; Tor, Y. ; Larsson, M. ; Daniels, G. ; Esener, Sadik ; Messmer, D. / Activity of the HMGB1-derived immunostimulatory peptide Hp91 resides in the helical C-terminal portion and is enhanced by dimerization. In: Molecular Immunology. 2014 ; Vol. 57, No. 2. pp. 191-199.
@article{703ed4d8b8884dc4bb6ada176e1a2656,
title = "Activity of the HMGB1-derived immunostimulatory peptide Hp91 resides in the helical C-terminal portion and is enhanced by dimerization",
abstract = "We have previously shown that an 18 amino acid long peptide, named Hp91, whose sequence corresponds to a region within the endogenous protein HMGB1, activates dendritic cells (DCs) and acts as adjuvant in vivo by potentiating Th1-type antigen-specific immune responses. We analyzed the structure-function relationship of the Hp91 peptide to investigate the amino acids and structure responsible for immune responses. We found that the cysteine at position 16 of Hp91 enabled formation of reversible peptide dimmers, monomer and dimmer were compared for DC binding and activation. Stable monomers and dimers were generated using a maleimide conjugation reaction. The dimer showed enhanced ability to bind to and activate DCs. Furthermore, the C-terminal 9 amino acids of Hp91, named UC1018 were sufficient for DC binding and Circular dichroism showed that UC1018 assumes an alpha-helical structure. The ninemer peptide UC1018 induced more potent antigen-specific CTL responses in vivo as compared to Hp91 and it protected mice from tumor development when used in a prophylactic vaccine setting. We have identified a short alpha helical peptide that acts as potent adjuvant inducing protective immune responses in vivo.",
keywords = "Adjuvant, Dendritic cells, Immune response, Peptide",
author = "R. Saenz and B. Messmer and D. Futalan and Y. Tor and M. Larsson and G. Daniels and Sadik Esener and D. Messmer",
year = "2014",
month = "2",
doi = "10.1016/j.molimm.2013.09.007",
language = "English (US)",
volume = "57",
pages = "191--199",
journal = "Molecular Immunology",
issn = "0161-5890",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Activity of the HMGB1-derived immunostimulatory peptide Hp91 resides in the helical C-terminal portion and is enhanced by dimerization

AU - Saenz, R.

AU - Messmer, B.

AU - Futalan, D.

AU - Tor, Y.

AU - Larsson, M.

AU - Daniels, G.

AU - Esener, Sadik

AU - Messmer, D.

PY - 2014/2

Y1 - 2014/2

N2 - We have previously shown that an 18 amino acid long peptide, named Hp91, whose sequence corresponds to a region within the endogenous protein HMGB1, activates dendritic cells (DCs) and acts as adjuvant in vivo by potentiating Th1-type antigen-specific immune responses. We analyzed the structure-function relationship of the Hp91 peptide to investigate the amino acids and structure responsible for immune responses. We found that the cysteine at position 16 of Hp91 enabled formation of reversible peptide dimmers, monomer and dimmer were compared for DC binding and activation. Stable monomers and dimers were generated using a maleimide conjugation reaction. The dimer showed enhanced ability to bind to and activate DCs. Furthermore, the C-terminal 9 amino acids of Hp91, named UC1018 were sufficient for DC binding and Circular dichroism showed that UC1018 assumes an alpha-helical structure. The ninemer peptide UC1018 induced more potent antigen-specific CTL responses in vivo as compared to Hp91 and it protected mice from tumor development when used in a prophylactic vaccine setting. We have identified a short alpha helical peptide that acts as potent adjuvant inducing protective immune responses in vivo.

AB - We have previously shown that an 18 amino acid long peptide, named Hp91, whose sequence corresponds to a region within the endogenous protein HMGB1, activates dendritic cells (DCs) and acts as adjuvant in vivo by potentiating Th1-type antigen-specific immune responses. We analyzed the structure-function relationship of the Hp91 peptide to investigate the amino acids and structure responsible for immune responses. We found that the cysteine at position 16 of Hp91 enabled formation of reversible peptide dimmers, monomer and dimmer were compared for DC binding and activation. Stable monomers and dimers were generated using a maleimide conjugation reaction. The dimer showed enhanced ability to bind to and activate DCs. Furthermore, the C-terminal 9 amino acids of Hp91, named UC1018 were sufficient for DC binding and Circular dichroism showed that UC1018 assumes an alpha-helical structure. The ninemer peptide UC1018 induced more potent antigen-specific CTL responses in vivo as compared to Hp91 and it protected mice from tumor development when used in a prophylactic vaccine setting. We have identified a short alpha helical peptide that acts as potent adjuvant inducing protective immune responses in vivo.

KW - Adjuvant

KW - Dendritic cells

KW - Immune response

KW - Peptide

UR - http://www.scopus.com/inward/record.url?scp=84886431329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886431329&partnerID=8YFLogxK

U2 - 10.1016/j.molimm.2013.09.007

DO - 10.1016/j.molimm.2013.09.007

M3 - Article

C2 - 24172222

AN - SCOPUS:84886431329

VL - 57

SP - 191

EP - 199

JO - Molecular Immunology

JF - Molecular Immunology

SN - 0161-5890

IS - 2

ER -